Brainsway Ltd (BWAY) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
Brainsway Ltd's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Brainsway Ltd's ROI in the fourth quarter of 2025? Brainsway Ltd achieved a return on average invested assets (ROI) of 10.53 % in its fourth quarter of 2025, which is below Brainsway Ltd's average return on investment, which stands at 12.85%.
ROI has improved compared to 4.22% in the third quarter of 2025, due to net income growth.
Within the Healthcare sector 123 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 0 to 816.
BrainsWay Ltd. is charting an ambitious course as a leader in the realm of noninvasive neurostimulation treatments. With a strategic push to expand its presence in East Asia, complemented by a robust network growth in the Western United States, the company is not only broadening its geographical footprint but also reinforcing its significant contributions to mental health treatment technologies. East Asian Expansion: BrainsWay recently announced the deployment of 15 additional Deep Transcranial Magnetic Stimulation (Deep TMS) systems across Taiwan and South Korea. This move amplifies its commitment to meet the increasing demand for advanced mental health treatments in East Asia. The technology is pioneering clinical interventions by offering noninvasive options for mental disorders, a significant shift from conventional treatments. This expansion serves to enhance accessibility to cutting-edge treatments while simultaneously cementing BrainsWay’s position in the Asian healthcare market.
In a striking move indicative of the rapidly evolving landscape of mental health treatment, BrainsWay, a leader in innovative transcranial magnetic stimulation (TMS) technologies, has announced a significant expansion into the U.S. East Coast. The company recently secured an order for 14 of its advanced Deep TMS devices from a prominent mental health network, underscoring the growing recognition of TMS as a viable therapeutic option for patients battling depression and other mental health disorders.As mental health issues increasingly take center stage in public discourse, and as demand for effective, non-invasive treatment options grows, BrainsWay s strategic expansion could not be more timely. This development comes as many healthcare providers are seeking to enhance their mental health offerings to meet the rising needs of their communities.
BrainsWay Pioneers New Frontiers in Mental Health Therapy as Israel’s Defense Ministry Endorses TMS for PTSDnn In a significant advancement for mental health treatment in Israel, BrainsWay Ltd. a prominent player in the field of non-invasive neurostimulation, has received approval from the Ministry of Defense s Rehabilitation Department for the reimbursement of its Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for patients diagnosed with post-traumatic stress disorder (PTSD). This milestone, announced on September 10, 2024, marks a pivotal moment for mental health care within the Israeli public hospital system, where the demand for innovative treatment options is surging.
The Context of PTSD in Israel PTSD has become a pressing issue in Israel, amplified by the country s unique sociopolitical landscape and security challenges. Combat veterans and civilians alike have been affected by traumatic events, leading to an increased focus on effective therapeutic interventions. Traditional treatment options such as psychotherapy and pharmacological interventions often fall short for many patients, underscoring an urgent need for alternative therapies. The endorsement of BrainsWay s Deep TMS therapy by the Ministry of Defense not only validates the need for such alternatives, but also shines a light on the broader movement towards integrating advanced technology into mental health treatment protocols.
BrainsWay, a leading provider of advanced neurostimulation treatments, recently appointed Dr. Richard A. Bermudes as its Chief Medical Officer. With decades of experience in the field of Transcranial Magnetic Stimulation (TMS), Dr. Bermudes is widely regarded as one of the preeminent clinicians in the United States. Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate specific areas of the brain. It has emerged as a promising therapy for a range of psychiatric disorders, including depression, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). As the demand for TMS treatments continues to grow, BrainsWay stands at the forefront, providing innovative and effective solutions.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
